Medincell and AbbVie have entered into a strategic licensing agreement to co-develop & commercialize up to 6 candidates by utilizing Medincell’s long-acting injectable technology platform. The 1st LAI program is selected with its formulation underway
Under the agreement, Medincell is entitled to receive $35M up front, $1.9B development & commercial milestones ($315M each) along with mid-single to low-double-digit net-sales-based royalties
Furthermore, Medincell will be responsible for formulation activities & preclinical development to advance the candidates into clinical evaluation while AbbVie will fund and handle the clinical development, regulatory approval, manufacturing & commercialization
Ref: Medincell | Image: Medincell
Related News:- AbbVie Receives the MHRA’s Marketing Authorisation of Aquipta (atogepant) for the Prevention of Migraines in Adults
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
